Kyiv’s troops make a modest breakthrough in the war against Russia, despite U.S. carping.
Review and Outlook: President Biden finally agrees to train Kyiv’s pilots to help win the air war in Ukraine. Images: AFP/Getty Images/U.S. Dept. of Defense Composite: Mark Kelly
The Biden Administration is leaking to the press that Ukraine is pursuing its counteroffensive against Russia all wrong. This looks like an unseemly attempt to shift blame from the White House if the war continues into a U.S. election year. But the pessimism is premature, and the criticism obscures some of Kyiv’s modest but notable recent gains on the battlefield.Continue reading your article with
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Jim Comer must make Eric Ciaramella testify on Joe Biden and UkraineEx-CIA official Eric Ciaramella is believed to be the whistleblower who fingered then-President Trump for allegedly demanding an investigation into Biden’s corruption to Ukraine military aid …
Read more »
Former Ukraine prosecutor makes explosive claims against Joe and Hunter Biden in new interviewEXCLUSIVE: Former Ukrainian Prosecutor General Viktor Shokin told Fox News he was fired in 2016 to prevent him from probing Burisma, the company where Hunter Biden worked.
Read more »
Hunter Biden’s business career is corrupt, and Joe Biden is fine with thatHunter Biden ran a corrupt influence-peddling lobbying racket, and his father, the president of the United States, says that it’s fine. This is conduct unbecoming the office of the president.
Read more »
Hunter Biden investigation: What's next for congressional Republicans' Biden family inquiriesWhen House Republicans return from their August recess, their investigations into the Biden family will focus on a handful of key people who played roles in the Department of Justice investigation of Hunter Biden.
Read more »
Adding immunity to human kidney-on-a-chip advances cancer drug testingT cell bispecific antibodies (TCBs) are an emerging class of immunotherapeutics with several TCBs approved by the FDA for the treatment of leukemias, lymphomas, and myelomas. TCBs label tumor cells with one of their ends, and attract immune cells with another end to coerce them into tumor cell killing. However, one major challenge in the development of TCBs are 'on-target, off-tumor' toxicities at sites in the body that also express TCB-targeted antigens. Scientists have now created an immune-infiltrated human kidney organoid-on-chip model that allows kidney toxicity of TCBs.
Read more »
Affirm stock advances as BNPL company easily tops revenue expectationsAffirm shares were powering nearly 7% higher in Thursday's after-hours action after the buy-now-pay-later operator topped expectations with its latest results.
Read more »